Pharma Q3: FDA inspection, US pricing market key
Piyush Nahar and Anurag Mantry analysts of Jefferies said, “We expect another muted quarter for the pharma sector led by weakness in US business. USFDA inspections and pricing in US market will continue to dominate the results. Recent comments from global peers have indicated that pricing scenario will likely remain unchanged in 2017.”
USFDA inspections and pricing in US market will continue to dominate the results for pharma companies. Photo: Pixabay